Gallium-containing magnesium alloy for potential use as temporary implants in osteosynthesis

In recent years magnesium alloys have been studied intensively with a view to their potential use in bioresorbable medical implants.In the present work the microstructure and the corrosion properties of a new bioresorbable Mg-4 wt%Ga-4 wt%Zn alloy and its variants with low Ca,Nd or Y additions were investigated.These alloys are of interest due to the efficacy of gallium as an element inhibiting bone resorption,osteoporosis,Paget's disease,and other illnesses.A severe plastic deformation technique of equal channel angular pressing(ECAP)was shown to provide the alloys with favorable mechanical properties.In addition,a desirable low rate of degradation in a simulated body fluid(Hanks'solution)was achieved.

UGT1A1杂合突变与伊立替康所致不良反应的真实世界研究

为了研究某三甲肿瘤专科医院患者UGT1A1基因型分布,探索真实世界中患者UGT1A1基因多态性与服用伊立替康后的不良反应的相关性,我们回顾性分析2017年5月至2021年12月该院42例接受UGT1A1基因检测的患者资料,总结其中31例服用伊立替康后其血液学以及非血液学不良反应的发生情况。结果表明:UGT1A128基因杂合突变率为21.9%,纯合突变率为4.9%,UGT1A16基因杂合突变率为31.5%,未检测到纯合突变型;本研究中UGT1A16及28杂合突变的患者较野生型患者血液学和非血液学不良反应未见显著性差异,血液学不良反应包括中性粒细胞减少、白细胞减少、血小板减少、血红蛋白减少,非血液学不良反应包括ALT/AST增高、ALP/GGT增高、胆红素增高、乏力、恶心、呕吐、迟发型腹泻;UGT1A16和28双位点突变的患者出现迟发性腹泻的发生率为100%。研究表明,UGT1A16和28双位点杂合突变的患者出现迟发性腹泻风险较高,需引起关注;UGT1A1杂合突变患者应用伊立替康后出现血液学及非血液学不良反应无显著性差异,但需进一步增加样本量证实这一结论。